Krabbe disease

Krabbe disease, also called globoid cell leukodystrophy, is an autosomal-recessive lysosomal disorder caused by deficient galactocerebrosidase (GALC) activity from biallelic pathogenic variants in GALC. Psychosine accumulation damages central and peripheral myelin. Infantile-onset disease and later-onset disease form a continuum but differ substantially in presentation, pace, and treatment decisions.1

Time-critical and urgent safety

An out-of-range Krabbe newborn screen is not a diagnosis, but it requires immediate coordination with the newborn-screening program and a Krabbe-experienced metabolic and transplant center. Confirmatory testing is time-critical because hematopoietic stem-cell transplantation has the best evidence when infantile-onset disease is identified and treated before symptoms.1

Call emergency services for breathing difficulty or color change, inability to clear secretions, prolonged or repeated seizures meeting the person's emergency plan, acute loss of alertness, or serious injury. Seek urgent assessment for persistent vomiting, dehydration, new choking, marked irritability or pain, or rapid loss of function.

Infantile and later-onset patterns

Infantile-onset Krabbe disease may begin after apparently typical early development with:

• marked irritability, unexplained crying, feeding difficulty, or reflux;
• stiffness, abnormal posturing, weakness, or loss of acquired skills;
• peripheral neuropathy, seizures, vision or hearing change;
• swallowing, secretion, temperature-regulation, or breathing difficulties.

Later-onset Krabbe disease can begin in childhood or adulthood. Presentations include progressive weakness or spasticity, gait change, neuropathic symptoms, ataxia, vision loss, seizures, or cognitive and psychiatric change. Course is highly variable; fixed age bands and survival estimates are not reliable guides for an individual.1

Screening and diagnosis

Newborn screening generally begins with low GALC activity in a dried-blood spot. Low activity alone can reflect carrier status or pseudodeficiency and does not diagnose Krabbe disease. Urgent second-tier blood psychosine testing, confirmatory leukocyte GALC activity, and GALC sequencing with deletion or duplication analysis help determine risk and diagnosis.1

In a symptomatic person, diagnosis combines deficient leukocyte GALC activity with molecular testing; psychosine, MRI, nerve-conduction, vision, hearing, and other assessments provide additional context. A variant of uncertain significance does not establish the diagnosis. Genotype and enzyme activity alone may not precisely predict later-onset timing.1

Disease-modifying and supportive care

Hematopoietic stem-cell transplantation can improve survival and neurologic outcomes in selected people, with the clearest benefit in presymptomatic infantile-onset disease treated in the first weeks of life. It is not a cure, carries substantial short- and long-term risks, and does not prevent all disability. Eligibility for symptomatic infantile or later-onset disease is individualized by an experienced transplant and metabolic team.1

Supportive care addresses pain and irritability, tone and movement, seizures, vision and hearing, breathing and sleep, feeding and nutrition, orthopedic health, mobility, positioning, and palliative goals. Medication, transplant, diet, equipment, and exercise decisions should reflect phenotype, current burden, and the person or family's priorities.

Swallowing and communication

Swallowing assessment should consider coughing or choking, respiratory symptoms, prolonged meals, fatigue, weight and hydration, reflux, secretions, pain, positioning, and motor control. Texture, pacing, posture, equipment, and tube-feeding decisions require direct assessment.1

Communication may remain age-expected in some later-onset presentations or change with motor, vision, hearing, fatigue, respiratory, or cognitive involvement. Do not infer understanding or decision-making ability from speech, movement, or disease stage. Address the person directly, allow time, and preserve established language and preferences.

AAC may include writing, alphabet or topic boards, stored messages, tactile or auditory supports, partner-assisted scanning, switches, and speech-generating systems. Trial access from actual vision, hearing, motor control, posture, and endurance. Include urgent messages and a reliable yes/no response, train partners, and keep a low-tech backup.3 For evaluation, trials, funding, and implementation, use the AAC device acquisition guide.

Coding

• ICD-10-CM E75.23: Krabbe disease.

The code does not distinguish infantile from later onset, screening status, transplant status, or current manifestations. Code associated conditions only when documented and supported by local rules.4

Sources

1. Wenger et al. Krabbe Disease, GeneReviews — screening, confirmation, phenotype variability, transplantation, supportive care, and genetic counseling.
2. Kwon et al. Consensus guidelines for newborn screening, diagnosis, and treatment of infantile Krabbe disease — time-critical confirmatory and transplant-center pathway (2018; PMID 29391017).
3. American Speech-Language-Hearing Association: Augmentative and Alternative Communication — individualized, multimodal AAC assessment.
4. Centers for Medicare & Medicaid Services: FY2026 ICD-10-CM definitions — E75.23 descriptor.

Review boundary

This page cannot diagnose Krabbe disease, interpret a newborn screen, determine transplant eligibility, or remotely assess seizures, pain, swallowing, or breathing. A positive newborn screen requires immediate specialist coordination, while emergencies require immediate local assessment. Transplant, medication, diet, equipment, mobility, and communication decisions require direct review with qualified teams and the person or family.